Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for behavioral symptoms in children with PDD
NCT00261508Phase 3Completed
- Sponsor
- Janssen Ortho
- Start
- Aug 1999
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in pervasive developmental disorder (PDD) and Autism Spectrum Disorder (ASD) comparing Risperidone with Placebo (2 arms). Primary endpoint: Change in the Irritability Subscale of the Aberrant Behavior Checklist at 8 weeks. Started Aug 1999; status: completed.
02
Drugs
risperidone
03
Conditions
pervasive developmental disorder (PDD)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00261508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261508.